Solara Active Pharma Sciences Limited

Equities

SOLARA

INE624Z01016

Pharmaceuticals

Market Closed - NSE India S.E. 07:43:49 2024-04-26 am EDT 5-day change 1st Jan Change
542.4 INR -3.29% Intraday chart for Solara Active Pharma Sciences Limited -1.70% +50.17%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Solara Active Pharma Sciences Limited Approves Appointment of Mohan Muthunarayanan as an Executive Director CI
Solara Active Pharma Gets Board Nod to Sell 100% Stake in SeQuent Penems MT
An undisclosed buyer agreed to acquire SeQuent Penems Private Limited from Solara Active Pharma Sciences Limited. CI
Solara Active Pharma Sciences Appoints CFO MT
Solara Active Pharma Sciences Limited Approves Appointment of Arun Kumar Baskaran as Chief Financial Officer CI
Solara Active Pharma Sciences' Human Resource Chief Resigns MT
Solara Active Pharma HR Chief Steps Down MT
Solara Active Pharma Sciences Limited Announces Resignation of Pagadala Srinivasan as Chief Human Resource Officer CI
Solara Active Pharma Sciences' CFO Resigns MT
Solara Active Pharma Sciences Limited Announces the Resignation of P.V. Raghavendra Rao as Chief Financial Officer CI
Transcript : Solara Active Pharma Sciences Limited, Q3 2024 Earnings Call, Feb 14, 2024
Solara Active Pharma Sciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Solara Active to Sell Subsidiary's Land MT
Solara Active Pharma Sciences Widens Consolidated Loss in Fiscal Q2 MT
Transcript : Solara Active Pharma Sciences Limited, Q2 2024 Earnings Call, Nov 14, 2023
Solara Active Pharma Sciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Fire Breaks Out at Solara Active Pharma's Puducherry, India Unit MT
Solara Active Pharma Names CFO MT
Solara Active Pharma Sciences Limited Appoints P V Raghavendra Rao as Chief Financial Officer CI
Solara Active Pharma Sciences Limited Announces Reconstitution of the Committees CI
Transcript : Solara Active Pharma Sciences Limited, Q1 2024 Earnings Call, Aug 14, 2023
Solara Active Pharma Sciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Solara Active Pharma's Tamil Nadu Plant in India Clears US FDA Inspection MT
Solara Active Pharma Sciences Limited Announces Resignation of Directors CI
Solara Active Pharma Sciences Limited Announces Executive Changes CI
Chart Solara Active Pharma Sciences Limited
More charts
Solara Active Pharma Sciences Limited is an India-based company offering diversified, commercial active pharmaceutical ingredients (APIs) and contract manufacturing services in over 70 countries. The Company operates through the API segment. Its commercial and research and development products include Albendazole, Aprepitant (Antiemetic), Artesunate, Brivaracetam (Antiepileptic), Bumetanide (Inj) (Loop Diuretic), Buspirone HCL (Anxiolytic), Cetirizine Dihydrochloride, Chlorpromazine Hydrochloride, Cinacalcet Hydrochloride (Calcimimetic Agent), Citicoline Sodium (Anticonvulsant), Colchicine (Antigout Agent), Colesevelam Hydrochloride, Cycloserine (Antitubercular), Ethacrynic Acid (Cardiovascular Agent), Hydralazine Hydrochloride (Anti-Hypertensive), Ibuprofen Sodium Dihydrate (Anti-inflammatory), Mesna (Antineoplastic Detoxifying Agent), Mirabegron (OAB Treatment), Pentoxifylline, and others. The Company works with pharmaceutical companies from North America, Europe, and Japan.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
542.4 INR
Average target price
350 INR
Spread / Average Target
-35.47%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. SOLARA Stock
  4. News Solara Active Pharma Sciences Limited
  5. Solara Active Pharma Sciences' : Promoter Pledge Decreases by 50%